Skip to content

Home
Immuno-Oncology
Therapies
- Approved Drugs
- Experimental Therapies
  - a
    - Actimmune
    - ABBV-181
    - ABBV-428
    - ABP798
    - Adagloxad Simolenin
    - ADU-741 (JNJ-64041809 )
    - ADXS-HER2
    - ADXS-PSA
    - AE37
    - AFM11
    - AFM13
    - AGEN1884
    - AGEN2034
    - ALKS 4230
    - AlloStim
    - AM0010 (Pegilodecakin)
    - AMG 211 (MEDI-565)
    - AMG 330
    - AMG 420
    - APVO414 (MOR209/ES414)
    - AST-VAC1
    - ATA520
    - AutoSynVax
  - b-c
  - D-F
  - G-I
    - GALE-301
    - Galinpepimut-S
    - Ganitumab
    - GBR 1342
    - GI-6207
    - GI-6301
    - GL-ONC1
    - Gliovac (ERC1671)
    - GP2
    - GRN-1201
    - GSK3174998
    - GWN323
    - HF10
    - ICT-107
    - ICT-121
    - IGN002
    - IMCgp100
    - IMP701
    - INCAGN1949
    - INO-1400
    - INO-3106
    - INO-5150
    - INO-9012
  - J-L
  - M-O
    - M7824
    - MAGE-A10 T-Cell Therapy
    - MBG453
    - MDNA55
    - MEDI0457
    - MEDI0562
    - MEDI0680
    - MGA012
    - MGD009
    - MK-4166
    - Mogamulizumab
    - MVA-BN Brachyury
    - MVI-118
    - NEO-PV-01
    - NeuVax (Nelipepimut-S)
    - NKR-2
    - NKTR-214
    - NY-ESO TCR
    - OncoVAX
    - ONCOS-102
  - P-S
    - PAN-301-1
    - PDR001
    - PDS0101
    - PF-04518600
    - PF-06801591
    - PNK-007
    - ProscaVax
    - PVRIG
    - Provenge (Sipuleucel-T)
    - REGN2810 (SAR439684)
    - REGN3767
    - Relatlimab
    - Reolysin
    - RG7802
    - RG7828
    - Rocapuldencel-T
    - rSIFN-co
    - SHR-1210
    - SL-701
    - SurVaxM
  - T-Z
    - TT12
    - Tedopi (OSE-2101)
    - Telomelysin (OBP-301)
    - TG4010
    - TPIV 200
    - TPIV200
    - Traumakine
    - TRX518
    - TSR-022
    - TSR-042
    - Utomilumab
    - ValloVax
    - Varlilumab
    - Vigil
    - Viagenpumatucel-L
    - VX15
    - VBI-1901
    - XmAb13676
    - VGX-3100
Categories
- T cells
- PD-1
- Melanoma
- Breast Cancer
- Cancer Vaccines
- FDA

Search for:

Resources

March 4, 2014May 19, 2014

Home » Resources

PH Association
National Institute of Health
Wikipedia – Pulmonary Hypertension
PH Canada
American Heart Association
Drugs.com
PH Central
Know Your PH
Clinical Trials

Leave a Comment Cancel reply

Your email address will not be published. Required fields are marked *

Comment

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.

Search for:

Never miss another immune-oncology update.

* indicates required

Email Address *

First Name *

Last Name

Recent IO Articles

Keytruda-Chemo Combo Shows Superior Anti-cancer Response in Metastatic NSCLC Phase 3 Trial

June 15, 2018
Men, Women Respond Differently to Immunotherapies Used in Advanced Cancer Treatment, Study Shows

June 13, 2018
Apogenix Updates Data on Asunercept, Prepares Submission for Conditional Marketing Authorization in Europe

June 12, 2018
Immunotherapy Targeting Tumor Mutations Leads to Complete Response in Advanced Breast Cancer Patient, NIH Reports

June 8, 2018
Foundation Medicine and Merck Collaborating to Develop Diagnostic Tests for Keytruda

June 6, 2018

You May Also Like…..

New Dosing Schedule Allows Patients to Receive Opdivo Every Four Weeks

March 8, 2018

Kite and Sagamo Are Partnering on Cell-engineered Treatments for Cancer

February 28, 2018

Tecentriq-Avastin Combo Keeps Advanced Kidney Cancer in Check, Roche Says

February 12, 2018

Visit Immuno-Oncology News's profile on Pinterest.

Immuno-Oncology News

BioNews Services, LLC
5307 E. Mockingbird Ln.
5th Floor
Dallas, TX 75206
Email: [email protected]
Phone: 1-800-936-1363

Recent Posts

Keytruda-Chemo Combo Shows Superior Anti-cancer Response in Metastatic NSCLC Phase 3 Trial

June 15, 2018
Men, Women Respond Differently to Immunotherapies Used in Advanced Cancer Treatment, Study Shows

June 13, 2018
Apogenix Updates Data on Asunercept, Prepares Submission for Conditional Marketing Authorization in Europe

June 12, 2018
Immunotherapy Targeting Tumor Mutations Leads to Complete Response in Advanced Breast Cancer Patient, NIH Reports

June 8, 2018

About Immuno-Oncology News
Keytruda (Pembrolizumab)
Contact Us
Privacy Policy
Terms of Service

Disclaimer:

Immuno-Oncology News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Copyright © 2013-2018 All rights reserved.

Pin It on Pinterest

Share This

Facebook
Twitter
Google+
Pinterest
LinkedIn

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. We never use your cookies for creepy ad retargeting that follows you around the web. Ok Read more